A PHASE III DOUBLE-BLIND, RANDOMISED, PARALLEL-GROUP SUPERIORITY TRIAL TO EVALUATE EFFICACY AND SAFETY OF THE COMBINED USE OF ORAL VICADROSTAT (BI 690517) AND EMPAGLIFLOZIN COMPARED WITH PLACEBO AND EMPAGLIFLOZIN IN PARTICIPANTS WITH TYPE 2 DIABETES, HYPERTENSION AND ESTABLISHED CARDIOVASCULAR DISEASE. (EASI¿-PROTKT)
- Registry ID
- 1378-0041
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- BOEHRINGER INGELHEIM INTERNATIONAL GMBH
- Start date
- 2026-03-05
- Last update
- 2025-06-13
Conditions
- HYPERTENSION
- TYPE 2 DIABETES
- CARDIOVASCULAR DISEASE
Related clinical trials
- A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ELECOGLIPRON COMPARED WITH ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS (ELUMINATE-2)
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-WEEKLY RO7795068 ADMINISTERED TO PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES
- EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-BIASED, ULTRA LONG-ACTING GLP-1RA, IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED, PLACEBO-CONTROLLED TRIAL (VESPER-5)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY
TO INVESTIGATE THE EFFECT OF ORFORGLIPRON ON THE INCIDENCE OF MAJOR ADVERSE
CARDIOVASCULAR EVENTS IN PARTICIPANTS WITH ESTABLISHED ATHEROSCLEROTIC
CARDIOVASCULAR DISEASE AND/OR CHRONIC KIDNEY DISEASE (ATTAIN-OUTCOMES)
- ZENITH: A PHASE 3 GLOBAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
TO EVALUATE THE EFFICACY AND SAFETY OF ZILEBESIRAN IN ADDITION TO STANDARD OF CARE
IN REDUCING MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULT PATIENTS WITH
HYPERTENSION NOT ADEQUATELY CONTROLLED AND WITH EITHER ESTABLISHED
CARDIOVASCULAR DISEASE OR HIGH RISK FOR CARDIOVASCULAR DISEASE
- EFFICACY AND SAFETY OF CAGRILINTIDE FOR WEIGHT MANAGEMENT IN PARTICIPANTS
WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (RENEW 2)
View on source registry